Necrosis News and Research

RSS

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

MRSA musculoskeletal infections increasing among children

Pediatric musculoskeletal Staphylococcus aureus bacterial infections have been evolving over the past decade, with more children diagnosed with the more virulent, methicillin-resistant Staphylococcus aureus today than 10 years ago.

28 Oct 2013

Gene variations in response to injury can impact clinical outcomes in TBI

Subtle variations in genes that regulate a person's inflammatory response to injury can impact clinical outcomes in TBI, according to a new study published in Journal of Neurotrauma.

18 Oct 2013

Finding highlights new ways of treating inflammation disorders

A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.

11 Oct 2013

Three Penn Medicine researchers awarded grants for neuromuscular disease research

The Muscular Dystrophy Association has awarded research grants totaling over $1,000,000 to three Penn Medicine researchers: James Shorter, PhD, associate professor of Biochemistry and Biophysics; Hansell Stedman, MD, associate professor of Surgery; and Lee Sweeney, PhD, director of the Center for Orphan Disease Research and Therapy.

9 Oct 2013

New research identifies protein that controls formation of different types of mature blood cells

New research in the Journal of Experimental Medicine identifies a protein that controls the formation of different types of mature blood cells - a finding that could be important to developing new treatments for blood diseases and helping realize the potential of regenerative medicine.

8 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

Stem cell-enriched fat grafting may prove an attractive option to major tissue augmentation

Stem cell-enriched fat grafting could become central to plastic and reconstructive surgery after the first randomised trial in humans confirms the technique’s excellent feasibility and safety.

30 Sep 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

...

3 Sep 2013

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined 9 biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis in whom prior pharmacological treatment had failed.

31 Aug 2013

Research findings could lead to new therapeutic approaches for liver cancer

Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.

30 Aug 2013

Reversing inflammation in fluid near brain's cortex may provide solution to Parkinson's disease

Reversing inflammation in the fluid surrounding the brain's cortex may provide a solution to the complex riddle of Parkinson's, according to researchers who have found a link between pro-inflammatory biomarkers and the severity of symptoms such as fatigue, depression and anxiety in patients with the chronic disease.

29 Aug 2013

Inflammatory status upregulated in first-episode schizophrenia

Patients with first-episode schizophrenia exhibit upregulation of key proinflammatory molecules, study findings show.

28 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

Necrosis News and Research

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

MRSA musculoskeletal infections increasing among children

Gene variations in response to injury can impact clinical outcomes in TBI

Finding highlights new ways of treating inflammation disorders

Three Penn Medicine researchers awarded grants for neuromuscular disease research

New research identifies protein that controls formation of different types of mature blood cells

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Stem cell-enriched fat grafting may prove an attractive option to major tissue augmentation

ACR journals publish guide that provides new treatments for children with systemic JIA

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Research findings could lead to new therapeutic approaches for liver cancer

Reversing inflammation in fluid near brain's cortex may provide solution to Parkinson's disease

Inflammatory status upregulated in first-episode schizophrenia

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News